Retatrutide: The Triple Agonist Peptide That Doesn't Know When to Stop (in the Best Way)

This content is for informational and research purposes only. Not medical advice. Consult a licensed physician before starting any hormone or peptide therapy.

In the weight loss peptide world, semaglutide was the revolution. It hit one receptor — GLP-1 — and the results were compelling enough that it became a cultural phenomenon, a dinner party topic, a punchline, and a shortage simultaneously. Then tirzepatide arrived and said, actually, we can hit two receptors. And the results were better. And everyone thought, well, that's probably where this ends.

It did not end there.

Retatrutide — Eli Lilly's LY3437943 — is a triple agonist peptide that hits GLP-1, GIP, and glucagon receptors simultaneously. If semaglutide is a one-trick pony, retatrutide showed up with three, and the Phase 2 clinical data suggests the third receptor wasn't just a cosmetic addition. The weight loss results in the trials were, to put it plainly, remarkable — and unlike anything seen in previous peptide research in this class.

This guide covers what retatrutide is, how it compares to semaglutide and tirzepatide, what the research shows about dosing, and — because you're on this site — how to properly track your retatrutide protocol when you're running dose escalations over months.

What Is Retatrutide? (The Triple Agonist Explained)

Retatrutide (LY3437943) is a once-weekly subcutaneous injection developed by Eli Lilly. It's a single peptide molecule that acts as an agonist at three distinct receptors:

• GLP-1 (glucagon-like peptide-1) receptor — reduces appetite, slows gastric emptying, improves insulin secretion. This is what semaglutide targets exclusively.
• GIP (glucose-dependent insulinotropic polypeptide) receptor — improves insulin sensitivity, modulates fat metabolism, and appears to enhance GLP-1 effects rather than counteracting them. Tirzepatide is a dual GLP-1/GIP agonist.
• Glucagon receptor — the third wheel that actually does a lot. Glucagon receptor activation increases energy expenditure and hepatic fat oxidation. This is what makes retatrutide's mechanism meaningfully different from its predecessors: it doesn't just suppress appetite, it also accelerates fat burning through a separate pathway.

The glucagon receptor component is the piece that makes endocrinologists lean forward. Pure glucagon is catabolic and raises blood sugar — not great. But in the context of simultaneous GLP-1 agonism, which suppresses glucagon-mediated hyperglycemia, you get the fat-burning benefits of glucagon receptor activation without the blood sugar downside. It's a neat pharmacological trick, and it appears to work remarkably well in practice.

Retatrutide vs Semaglutide vs Tirzepatide

Let's look at what the data actually shows, because the retatrutide vs semaglutide and retatrutide vs tirzepatide comparisons are not subtle.

The Phase 2 trial published in the New England Journal of Medicine in 2023 showed participants on the highest retatrutide dose (12mg) lost an average of 24.2% of body weight over 48 weeks. For context, that's roughly twice the weight loss seen with semaglutide and meaningfully more than tirzepatide in comparable trials. The dropout-adjusted numbers are still impressive.

It's worth noting these are Phase 2 trials, which are designed primarily around safety and dose-finding rather than the larger population studies that Phase 3 delivers. Retatrutide's Phase 3 program is ongoing. But the Phase 2 signal is strong enough that anyone in the research peptide space is paying close attention.

The jump from semaglutide to tirzepatide was notable. The jump from tirzepatide to retatrutide appears, based on available data, to be larger still. The glucagon receptor component is not decorative.

The Retatrutide Dosing Protocol — What the Research Shows

The retatrutide dosing schedule used in the Phase 2 trial followed a dose escalation approach — the same general strategy used with tirzepatide and semaglutide, where you start low and titrate up over months to allow GI tolerance to develop. Jumping to the maximum dose from week one is a reliable way to be extremely nauseated and discontinue the protocol before it has a chance to work.

The escalation schedule from the trial:

• Weeks 1–4: 2mg once weekly
• Weeks 5–8: 4mg once weekly
• Weeks 9–12: 8mg once weekly
• Weeks 13+: 12mg once weekly (maintenance)

Some protocols use a slower escalation with a 6mg intermediate step between 4mg and 8mg, which appears to improve GI tolerance in people who find the jump to 8mg aggressive. The right approach depends on individual response — some people escalate without issue, others need more runway.

All injections are subcutaneous, typically in the abdomen, outer thigh, or upper arm. Rotating sites is standard practice and worth logging. The half-life of retatrutide is approximately 6 days, making once-weekly injection appropriate for maintaining steady-state levels.

This is where logging becomes operationally important: when you're on a dose escalation protocol and you skip a dose, delay significantly, or need to hold at a lower dose due to side effects, you need to know exactly where you are in the schedule. "I think I'm on 8mg now" is not a protocol. It's a guess dressed up as a protocol.

Why Tracking Your Retatrutide Protocol Actually Matters

Tracking matters with any compound, but with retatrutide specifically — and with GLP-1 class peptides generally — the dose escalation structure makes logging especially important for a few distinct reasons.

You need to know where you are in the escalation

If you're three months in, you should know whether you're at 8mg or 12mg without having to do mental archaeology through your memory. This sounds trivially obvious. It is less trivially obvious at 11pm when you're loading a syringe after a long day and you can't remember if last week was the last week of 8mg or the first week of 12mg. Log it. Know where you are.

Correlate weight and measurements with dose changes

The most useful data point on a retatrutide weight loss protocol isn't just "am I losing weight" — it's "which dose level produced the most meaningful response, and did that change when I escalated?" This requires logging body weight against the current dose so you can see the dose-response relationship in your own data, not just in the trial averages. Body composition and waist measurements are even more useful than scale weight for tracking retatrutide's metabolic effects.

Side effect windows

Nausea, reduced appetite, and GI symptoms on GLP-1 class peptides tend to be worst in the first 1–2 weeks after each dose escalation, then attenuate as tolerance develops. If you're logging your symptoms alongside your dose history, you can see this pattern clearly. You can also see if a symptom you're experiencing started at escalation — which is usually GI tolerance — or appeared mid-dose-level, which might be worth flagging to your physician.

Track retatrutide doses for accountability to your own protocol

A weekly injection is easy to miss. Travel, disrupted routine, simply forgetting — the same adherence problem that plagues TRT injection tracking applies here. A missed dose on a weekly peptide protocol matters more than a missed dose on a twice-weekly TRT protocol, because each injection represents a full week's coverage. ZAP handles scheduling and reminders for retatrutide alongside any other compounds you're running concurrently.